Which phase is focused on monitoring long-term safety after a drug has been marketed?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $25.99Unlock all

Prepare for the Adverse Effects and Toxicology Test with our comprehensive format. Utilize flashcards and multiple-choice questions, complete with hints and explanations to ace your exam!

Multiple Choice

Which phase is focused on monitoring long-term safety after a drug has been marketed?

Explanation:
Phase 4 is the post-marketing phase focused on long-term safety after a drug is marketed. Once a drug reaches broad real-world use, it’s exposed to a much larger and more diverse group of people, often over longer periods. Rare adverse effects or those that only appear with long-term exposure, aging, or interactions with other medications may not show up in earlier trials. Phase 4 involves ongoing safety monitoring, spontaneous adverse event reporting, and sometimes dedicated long-term or real-world studies. This surveillance can lead to updated labeling, warnings, restricted use, or even withdrawal if new risks arise.

Phase 4 is the post-marketing phase focused on long-term safety after a drug is marketed. Once a drug reaches broad real-world use, it’s exposed to a much larger and more diverse group of people, often over longer periods. Rare adverse effects or those that only appear with long-term exposure, aging, or interactions with other medications may not show up in earlier trials. Phase 4 involves ongoing safety monitoring, spontaneous adverse event reporting, and sometimes dedicated long-term or real-world studies. This surveillance can lead to updated labeling, warnings, restricted use, or even withdrawal if new risks arise.

More Multiple Choice Questions
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy